Adult
stem cells may offer hope for patients with multiple sclerosis (MS) and other
neurodegenerative diseases, new research suggests.
MS
is a chronic, progressive, degenerative disorder that affects nerve fibers in
the brain and spinal cord. It is widely believed to be an autoimmune disease, a
condition in which the immune system attacks components of the body as if they
are foreign.
A
fatty substance, called myelin, surrounds and insulates nerve fibers and
facilitates the conduction of nerve impulse transmissions. MS is characterized by
damage to myelin (called demyelination) caused by the destruction of
specialized cells (oligodendrocytes) that form the myelin. Demyelination causes
scarring and hardening (sclerosis) of nerve fibers usually in the spinal cord,
brain stem and optic nerves, which slows nerve impulses and results in
weakness, numbness, pain and vision loss.
Because
different nerves are affected at different times, MS symptoms often worsen,
improve and develop in different areas of the body. Early symptoms of the
disorder may include vision changes, such as blurred vision or blind spots,
followed by muscle weakness.
MS
affects over 250,000-500,000 people in the United States and may affect 2.5
million people worldwide. Northern Europe and the northern United States have
the highest prevalence, with more than 30 cases per 100,000 people. MS affects
two to three times as many women as men, and affects Caucasians more often.
Most individuals experience their first signs or symptoms between 20 and 40
years of age. Children of parents with MS have a higher rate of incidence
(30-50 percent).
An
adult stem cell is an undifferentiated cell found among differentiated cells in
a tissue or organ; it can renew itself and can differentiate to yield the major
specialized cell types of the tissue or organ. The primary roles of adult stem
cells in a living organism are to maintain and repair the tissue in which they
are found.
Both
adult and embryonic stem cells are taken from living human tissue. Adult stem
cells are readily available in many different areas of the human body and do
not harm the individual from whom they are taken. Embryonic stem cells are
harvested from living embryos and the developing human life must be killed in
order to extract the stem cells.
Research
on adult stem cells has recently generated excitement and adult blood forming
stem cells from bone marrow have been used in transplants for 30 years. Certain
kinds of adult stem cells seem to have the ability to differentiate into a
number of different cell types, given the right conditions.
If
this differentiation of adult stem cells can be controlled in the laboratory,
these cells may become the basis of therapies for many serious common diseases.
Some examples of potential treatments include replacing the dopamine-producing
cells in the brains of Parkinson's patients, developing insulin-producing cells
for type I diabetes and repairing damaged heart muscle following a heart attack
with cardiac muscle cells.
Research
into adult stem cells has been fueled by their abilities to divide or
self-renew indefinitely and generate all the cell types of the organ from which
they originate - potentially regenerating the entire organ from a few cells.
Unlike embryonic stem cells, the use of adult stem cells in research and therapy
is not controversial because the production of adult stem cells does not
require the destruction of an embryo. Adult stem cells can be isolated from a
tissue sample obtained from an adult. They have mainly been studied in humans
and model organisms such as mice and rats.
Researchers
from Israel explained that no specific treatment exists for patients with MS
who fail to respond to conventional immunosuppressive and immunomodulating
modalities.
The
scientists outlined two ultimate goals of MS treatment: first, to eliminate
self-reactive lymphocytes and to prevent new development of self-reactivity by
induction of self-tolerance and second, to attempt regeneration and repair of
existing damage.
In
the case of MS, there is a need to stop the ongoing process of inflammation
against the central nervous system (CNS) as well as to recover existing
neurological deficits caused by the autoimmune process. The researchers believe
that cell therapy stands out as the most rationale approach for neurological
regeneration.
The
study investigated the feasibility and efficacy of enriched autologous
mesenchymal stromal cells (MSC) injected intrathecally (into the spinal canal)
and intravenously (into a vein) to induce immunomodulation and neuroprotection
and possibly facilitate the repair of the CNS in patients with MS and other
neurodegenerative disorders.
From
the results, the study authors concluded that bone marrow cells may provide a
source of stem cells that may migrate into the inflamed CNS and differentiate
into cells expressing neuronal and glial cell markers. The researchers are
currently evaluating the safety of a similar therapeutic approach in a small
group of patients with MS and other neurodegenerative diseases.
Adult
stem cell research (ASCR) has led to successful treatments in over seventy
diseases and conditions, and new uses are constantly being discovered. Adult
stem cells are currently being used to treat and cure patients who suffer from
diseases such as cancer, liver disease and Parkinson's disease, while embryonic
stem cells have yet to successfully retreat any conditions.
For
a list of diseases that have been treated with adult stem cells, please click here.
For the latest in adult stem cell research, please visit SCI Research
Advancement or the Stem Cell Research Institute.
For
more information on multiple sclerosis, please visit Natural Standard's Conditions
database.